- Home
- ENVB vs ADXN Comparison
ENVB vs ADXN Comparison
Compare ENVB & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENVB | ADXN |
|---|---|---|
| Founded | 1994 | 2002 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 8.6M |
| IPO Year | 2000 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ENVB | ADXN |
|---|---|---|
| Price | $1.40 | $6.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 132.7K | 4.6K |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,914,675.00 | N/A |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $5.41 |
| 52 Week High | $13.25 | $12.05 |
Technical Indicators
Market Signals| Indicator | ENVB | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 36.40 | 43.03 |
| Support Level | $0.60 | $5.75 |
| Resistance Level | $1.58 | $7.37 |
| Average True Range (ATR) | 0.12 | 0.46 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 35.19 | 19.05 |
Price Performance
Historical ComparisonAbout ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.